Stifel still upbeat on IntriCon’s long-term prospects after Q3 report

Stifel analyst Jonathan Block said IntriCon’s (IIN) stock might see some selling pressure after the company’s Q3 revenue of $30.1M came in modestly below his $30.5M forecast, but he remains upbeat on the company’s long-term prospects given his view that it is still very early in the process of IntriCon benefiting from Medtronic’s (MDT) 670G/690G product cycles. Block keeps a Buy rating and $70 price target on shares of IntriCon, which are down $9.77, or 22%, to $34.52 in morning trading.
https://thefly.com/landingPageNews.php?id=2818503